- Home
- RDWR vs COGT Comparison
RDWR vs COGT Comparison
Compare RDWR & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDWR
- COGT
- Stock Information
- Founded
- RDWR 1996
- COGT 2014
- Country
- RDWR Israel
- COGT United States
- Employees
- RDWR N/A
- COGT N/A
- Industry
- RDWR EDP Services
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- RDWR Technology
- COGT Health Care
- Exchange
- RDWR Nasdaq
- COGT Nasdaq
- Market Cap
- RDWR 889.9M
- COGT 1.0B
- IPO Year
- RDWR 1999
- COGT 2018
- Fundamental
- Price
- RDWR $19.72
- COGT $4.71
- Analyst Decision
- RDWR Hold
- COGT Buy
- Analyst Count
- RDWR 4
- COGT 7
- Target Price
- RDWR $27.00
- COGT $14.17
- AVG Volume (30 Days)
- RDWR 127.9K
- COGT 1.2M
- Earning Date
- RDWR 05-07-2025
- COGT 05-06-2025
- Dividend Yield
- RDWR N/A
- COGT N/A
- EPS Growth
- RDWR N/A
- COGT N/A
- EPS
- RDWR 0.14
- COGT N/A
- Revenue
- RDWR $274,880,000.00
- COGT N/A
- Revenue This Year
- RDWR $9.54
- COGT N/A
- Revenue Next Year
- RDWR $7.54
- COGT N/A
- P/E Ratio
- RDWR $158.43
- COGT N/A
- Revenue Growth
- RDWR 5.20
- COGT N/A
- 52 Week Low
- RDWR $16.12
- COGT $5.30
- 52 Week High
- RDWR $25.00
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- RDWR 34.22
- COGT 25.93
- Support Level
- RDWR $22.07
- COGT $6.31
- Resistance Level
- RDWR $22.23
- COGT $7.49
- Average True Range (ATR)
- RDWR 0.53
- COGT 0.37
- MACD
- RDWR -0.17
- COGT -0.16
- Stochastic Oscillator
- RDWR 5.70
- COGT 0.84
About RDWR Radware Ltd.
Radware Ltd provides cyber security and application delivery solutions. The company provides solutions for cloud, on-premises, and software-defined data centers (SDDC). The solutions of the company secure the digital experience by providing infrastructure, application, and network protection and availability services to enterprises globally. The business segments of the company are Radware's Core Business and The Hawks' Business. The company derives maximum revenue from Radware's Core Business. The company generates maximum revenue from the United States.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.